Kynmobi Safe, Effective for ‘Off’ Periods... - Cure Parkinson's
Kynmobi Safe, Effective for ‘Off’ Periods Over Long Term, Ongoing Trial Reports
"Sunovion‘s Kynmobi (apomorphine hydrochloride), a sublingual film treatment for “off” episodes in people with Parkinson’s disease, has a manageable safety profile and maintains efficacy over up to nearly a year of use, interim data from an ongoing Phase 3 trial show.
...
Most (85%) reported at least one adverse event that emerged following treatment; the most common included nausea (27%), yawning (12%), dizziness (11%), and sleepiness (11%). The most common adverse events affecting the mouth — which are of interest with a sublingual medication — were redness (8%) and lip swelling (5%). Fainting occurred in 2% of participants.
Adverse events led to treatment discontinuation in 31% of participants; the most common reasons for discontinuing were nausea (6%), lip swelling (3%), and dizziness (2%)."
Not what you're looking for?
You may also like...
Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease (Nov 20, 2020)
